Log in

NASDAQ:BEAT - BioTelemetry Stock Price, Forecast & News

$53.52
-0.29 (-0.54 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$53.04
Now: $53.52
$54.27
50-Day Range
$46.27
MA: $50.69
$55.27
52-Week Range
$37.07
Now: $53.52
$78.50
Volume128,241 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio50.02
Dividend YieldN/A
BetaN/A
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:BEAT
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1,500
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.


BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) issued its quarterly earnings data on Tuesday, November, 5th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.50 by $0.02. The medical research company had revenue of $111.30 million for the quarter, compared to analysts' expectations of $111.19 million. The firm's revenue was up 11.3% on a year-over-year basis. During the same period last year, the company earned $0.53 earnings per share. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for BioTelemetry.

What price target have analysts set for BEAT?

6 equities research analysts have issued twelve-month target prices for BioTelemetry's shares. Their forecasts range from $54.00 to $87.00. On average, they anticipate BioTelemetry's stock price to reach $72.67 in the next year. This suggests a possible upside of 35.8% from the stock's current price. View Analyst Price Targets for BioTelemetry.

What is the consensus analysts' recommendation for BioTelemetry?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry.

Has BioTelemetry been receiving favorable news coverage?

Press coverage about BEAT stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioTelemetry earned a news impact score of 2.0 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for BioTelemetry.

Are investors shorting BioTelemetry?

BioTelemetry saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,830,000 shares, an increase of 5.6% from the January 15th total of 2,680,000 shares. Based on an average daily trading volume, of 260,800 shares, the days-to-cover ratio is currently 10.9 days. Currently, 8.6% of the shares of the stock are short sold. View BioTelemetry's Current Options Chain.

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), ABIOMED (ABMD), Netflix (NFLX), Square (SQ), Paypal (PYPL), Adobe (ADBE), Twilio (TWLO) and Advanced Micro Devices (AMD).

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 44)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)
  • Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 55)

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by many different of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (10.17%), Credit Suisse AG (3.21%), State Street Corp (2.92%), Loomis Sayles & Co. L P (1.75%), Pembroke Management LTD (1.63%) and Rothschild & Co. Asset Management US Inc. (1.63%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which major investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including THB Asset Management, Vident Investment Advisory LLC, Millrace Asset Group Inc., Rothschild & Co. Asset Management US Inc., Principal Financial Group Inc., Arizona State Retirement System, Pinebridge Investments L.P. and Public Sector Pension Investment Board. Company insiders that have sold BioTelemetry company stock in the last year include Kirk E Gorman and Peter Ferola. View Insider Buying and Selling for BioTelemetry.

Which major investors are buying BioTelemetry stock?

BEAT stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Pembroke Management LTD, Loomis Sayles & Co. L P, Kirr Marbach & Co. LLC IN, Barclays PLC, Royce & Associates LP, Russell Investments Group Ltd. and Argent Capital Management LLC. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $53.52.


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  673
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel